3rd Circ. Rejects 'Close' Case For Preemption In Fosamax MDL
By Carla Baranauckas · September 20, 2024, 8:42 PM EDT
A U.S. Food and Drug Administration letter denying changes to the label of Merck's osteoporosis drug Fosamax does not count as a final agency action triggering federal preemption of state law...
To view the full article, register now.